Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EBIT: 2023-2025

Historic EBIT for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$55.1 million.

  • NewAmsterdam Pharma Co N.V's EBIT fell 120.55% to -$55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.9 million, marking a year-over-year decrease of 10.21%. This contributed to the annual value of -$176.3 million for FY2024, which is 3.65% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its EBIT stood at -$55.1 million for Q3 2025, which was down 54.74% from -$35.6 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's EBIT registered a high of -$25.0 million during Q3 2024, and its lowest value of -$68.9 million during Q1 2025.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's EBIT had a median value of -$49.6 million in 2023 and averaged -$47.2 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's EBIT surged by 49.55% in 2024 and then plummeted by 120.55% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's EBIT stood at -$51.1 million in 2023, then climbed by 15.36% to -$43.2 million in 2024, then tumbled by 120.55% to -$55.1 million in 2025.
  • Its EBIT was -$55.1 million in Q3 2025, compared to -$35.6 million in Q2 2025 and -$68.9 million in Q1 2025.